Table 5. Levels of 7 parameters in patients receiving different chemotherapy regimens throughout chemotherapy.
Parameter | Regimen | Prechemotherapy | Prior to the last cycle of chemotherapy | 6 m after chemotherapy |
---|---|---|---|---|
Mean±SD | Mean±SD | Mean±SD | ||
TC | Anthracycline | 5.09±1.09 | 5.25±1.15 | 4.93±0.80 |
Taxane | 5.10±1.09 | 5.18±0.89 | 4.87±1.07* | |
Anthracycline+taxane | 5.10±1.09 | 5.19±1.02 | 5.05±1.05 | |
TG | Anthracycline | 1.68±0.81 | 2.14±1.52* | 2.13±2.05 |
Taxane | 1.60±1.00 | 2.04±1.13* | 2.00±1.91* | |
Anthracycline+taxane | 1.68±0.98 | 2.21±1.56* | 1.85±1.12* | |
LDL-C | Anthracycline | 2.89±0.79 | 3.05±0.91 | 2.62±0.64* |
Taxane | 2.84±0.74 | 2.92±0.69 | 2.59±0.76*& | |
Anthracycline+taxane | 2.87±0.78 | 3.01±0.83* | 2.78±0.80 | |
HDL-C | Anthracycline | 1.39±0.41 | 1.26±0.29*& | 1.38±0.36 |
Taxane | 1.35±0.32 | 1.24±0.34*& | 1.34±0.35 | |
Anthracycline+taxane | 1.32±0.27 | 1.16±0.27* | 1.34±0.30 | |
HCY | Anthracycline | 9.11±2.38 | 9.39±2.86 | 8.81±2.05 |
Taxane | 9.60±2.35 | 9.10±2.23* | 9.84±2.13# | |
Anthracycline+taxane | 9.36±2.42 | 8.72±2.51* | 9.59±2.96 | |
UA | Anthracycline | 283.41±60.69 | 296.22±77.25* | 293.67±54.52 |
Taxane | 266.48±51.59 | 268.12±58.50# | 292.36±57.36* | |
Anthracycline+taxane | 268.77±56.57 | 268.52±54.62# | 289.47±62.50* | |
BMI | Anthracycline | 22.27±2.55 | 22.37±2.67 | 22.43±2.74 |
Taxane | 22.46±2.86 | 22.92±2.92*# | 22.66±2.89 | |
Anthracycline+taxane | 22.50±2.60 | 22.89±2.88* | 22.85±2.77* |
TC: total cholesterol (mmol/L); TG: triglycerides (mmol/L); LDL-C: low-density lipoprotein cholesterol (mmol/L); HDL-C: high-density lipoprotein cholesterol (mmol/L); HCY: homocysteine (μmol/L); UA: uric acid (μmol/L); BMI: body mass index; 6 m: 6 months; SD: standard deviation
*: P<0.05 compared with baseline levels (prechemotherapy levels)
#: P<0.05 compared with the group receiving the anthracycline chemotherapy regimen
&: P<0.05 compared with the group receiving the anthracycline + taxane chemotherapy regimen